Russia develops artificial liver with clinical trials set for 2027

Moscow is currently developing Russia's first artificial liver system, a device designed to temporarily perform the functions of a damaged organ. Anatoly Garbuzov, the head of the capital's Department of Investment and Industrial Policy, announced the ambitious medical project.

• The project is being developed by the Artsellens plant in partnership with leading scientific institutes.
• The device aims to purify blood, support metabolism, and ensure protein synthesis.
• Clinical trials of the new medical technology are scheduled to begin in 2027.
• Production of the system is planned to be set up in a special economic zone in Moscow.

Functionality and Medical Purpose The innovative device is engineered to take over the primary functions of the liver when a patient's own organ fails. It is designed to cleanse the blood of toxins, support metabolic processes, and facilitate necessary protein synthesis. This multi-functional approach will help sustain critical patients until further medical intervention becomes possible.

Impact on Organ Transplants The technology is expected to serve as a vital bridge for patients awaiting a liver transplant or to provide damaged liver tissues with sufficient time to recover naturally. By temporarily assuming the organ's workload, the system significantly improves survival prospects for individuals suffering from severe hepatic failure.

Production Plans and Future Outlook The manufacturing of the artificial liver system will be organized within Moscow's special economic zone, providing a robust industrial and scientific base. This initiative highlights the continuous advancement of domestic medical technologies aimed at solving complex healthcare challenges.